


DEVELOPING A GLOBAL HEALTH BUSINESS CASE SOLUTION FOR DRUG SUSCEPTIBILITY TESTING AND ANTIMICROBIAL RESISTANCE


CPTR Workshop
March 23, 2017

SOME LESSONS WE HAVE LEARNED...

INDUSTRY ANALYSIS – WHY DIAGNOSTICS COMPANIES FAIL

VERY HIGH ATTRITION RATE DURING EARLY STAGES






“UNSINKABLE.”

**SAFETY APPARATUS OF THE
TITANIC.**

Mr. Franklin, vice-president of the International Mercantile Marine, which controls the White Star Line, issued in New York yesterday the following statement:—

“We are perfectly satisfied that the Titanic is unsinkable. We are absolutely certain that she is able to withstand any damage. She may be down by the head, but would float indefinitely in that condition.”



Product
Development

Implementation
& scale up

AGENDA

10:15 am – 10:25 am

Session Introduction

Jim Gallarda (Bill & Melinda Gates Foundation)

10:25 am – 10:40 am

Business Models for Sustaining Biomedical Databases: The Case for ReSeqTB

Anita Suresh (McGill University)

10:40 am – 10:55 am

Does a Sustainable Business Model Need a New Global Health Institution? Lessons from the GAVI-Alliance

Kristin Ingstad Sandberg (Fridtjof Nansen Institute)

10:55 am – 11:10 am

Adoption of Real-time, Low Cost, Portable Whole Genome Sequencing for Point-of-care Drug Susceptibility and Antimicrobial Resistance Testing

Richard Compton (Oxford Nanopore Technologies)

11:10 am – 11:45 am

Question & Answer

11:45 am – 12:15 pm

Closing Remarks

Jim Gallarda (Bill & Melinda Gates Foundation)

Steve Bradley (TB Alert)